Human IL1RAP Antibody - Nidanilimab Biosimilar
| Product | Unit size | Cat. code | Docs. | Qty. | Price | |
|---|---|---|---|---|---|---|
|
Anti-hIL1RAP-hIgG1 Human IL-1RAP (Nidanilimab) antibody - Human IgG1 |
Show product |
100 µg 3 x 100 µg |
hil1rap-mab1
|
|
Anti-human IL-1R3 (IL1RAP) - Nidanilimab biosimilar - CAS #2171061-85-9
InvivoGen also offers:
Anti-hIL1RAP-hIgG1 is a biosimilar antibody of Nidanilimab, a human interleukin 1 receptor accessory protein (IL1RAP or IL1R3) antibody that blocks IL-1α and IL-1β signaling. This monoclonal antibody (mAb), also known as Nadunolimab or CAN04, is under investigation for the treatment of various solid cancer types, including pancreatic cancer and refractory non-small-cell lung cancer (NSCLC).
Anti-hIL1RAP-hIgG1 comprises the variable region of Nidanilimab and the IgG1 constant region of Nidanilimab for high effector functions.
This mAb can be used together with HEK-Blue™ IL-1β cells for screening and neutralization assays to block IL-1 signaling induced by recombinant human IL-1β (see figure). Nidanilimab also inhibits the signaling of human IL-1α, IL-33, and IL-36α (data not shown).
Key features
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct was verified.
- The absence of endotoxins is determined by the EndotoxDetect™ assay.
All InvivoGen products are for internal research use only, and not for human or veterinary use.
Figures
Specifications
Application: Neutralization assay, ELISA
Isotype: Human IgG1
Recommended isotype control: Human IgG1
Target: Human IL-1R3, IL-1RAP, IL1RAP, IL-1RAcP
Species reactivity: Human
Clone: Nidanilimab, Nadunolimab, CAN04, CANFOUR
Cas number: 2171061-85-9
Source: CHO cells
Production: Animal-free
Purification: Protein A
Molecular weight: 144.5 kDa
Physical form: Lyophilized
Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Preservative: Azide-free
Reconstitution buffer: Sterile water (not provided)
Purity: ≥ 95 %
Quality control: Each lot is functionally tested and validated.
Back to the topContents
Anti-hIL1RAP-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:
- hil1rap-mab1: 100 µg
- hil1rap-mab1-03: 3 x 100 µg
The product is shipped at room temperature.
Upon receipt, store lyophilized antibody at -20 °C.
Lyophilized product is stable for at least 1 year.
Avoid repeated freeze-thaw cycles.
Details
Nidanilimab/Nadunolimab background
Nidanilimab (CAN04, Nadunolimab) is a fully humanized monoclonal antibody (mAb) that targets interleukin-1 receptor accessory protein IL-1R3, also known as IL-1RAP or IL-1RAcP [1].
IL-1RAP is a co-receptor essential for signaling by several IL-1 family cytokines, including IL-1α, IL-1β, IL-33, and IL-36 [1]. IL-1RAP mediates signal transduction by associating with the primary ligand-binding receptors IL-1R1, ST2, or IL-1R6. This activates the transcription factorsNF-κB and AP-1, leading to the expression of pro-inflammatory genes [1].
Nidanilimab was designed to disrupt the IL-1RAP-dependent signaling pathways and to induce antibody-dependent cellular cytotoxicity (ADCC) in IL-1RAP-expressing cells. As IL-1RAP is found to be overexpressed in multiple hematological and solid cancers, it is considered a promising therapeutic target. Multiple clinical trials were launched to assess the safety, tolerability, and efficacy of Nidanilimab, both as a monotherapy and in combination with chemotherapy regimens [1-3].
References:
1. Fields JK, et al., 2021. Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor. Front Immunol. ;12:779100.
2. Robbrecht D, et al., 2022. First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours. Br J Cancer. 126(7):1010-1017.
2. Frenay J, et al., 2022. IL-1RAP, a Key Therapeutic Target in Cancer. Int J Mol Sci. ;23(23):14918.